Q-omics provides the consensus-scored CYSLTR2 profile across patient tissues and cancer cell-line models. CYSLTR2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CYSLTR2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CYSLTR2 RNA expression shows 16,590 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where CYSLTR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYSLTR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYSLTR2 survival associations across molecular data types. CYSLTR2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYSLTR2 RNA expression–survival associations across cancer types. High CYSLTR2 expression shows unfavorable associations in UVM, but favorable associations in MESO, CESC, ACC, LUAD and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CYSLTR2 RNA expression.
This table summarizes CYSLTR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYSLTR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYSLTR2 shows lower tumor expression in COAD, KICH, UCEC and LUAD and higher tumor expression in HNSC and THCA. The HNSC box plot shows higher CYSLTR2 RNA expression in tumor versus normal tissue (log2 FC = +0.545, t-test p < 0.001).
This table shows molecular features associated with CYSLTR2 in patient tissues and cancer cell lines. In patient samples, CYSLTR2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYSLTR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LIVER.
